|
Market Closed -
Nasdaq
00:00:00 15/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 426.11 USD | +3.21% |
|
+3.15% | +30.19% |
| 10-13 | Goldman Sachs Adjusts Price Target on Amgen to $475 From $450 | MT |
| 10-12 | Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 230B | |||||
| 1,077B | |||||
| 612B | |||||
| 501B | |||||
| 364B | |||||
| 353B |
- Stock Market
- Stocks
- AMGN Stock
- Charts Amgen Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
